EDIT
Editas Medicine, Inc. (NASDAQ)
Healthcare — Biotechnology
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $503.35M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.50 |
| EPS (TTM) | $-1.14 |
| Dividend Yield | - |
| Profit Margin | -281.59% |
| Revenue Growth | -39.20% |
| ROE | -326.07% |
| Debt/Equity | 392.40 |
| Recommendation | None |
| Analyst Target | $5.78 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 79.4 |
| Beta | 2.10 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $4.54 |
| 52-Week Low | $1.66 |
| 50-Day Avg | $2.90 |
| 200-Day Avg | $2.68 |
| Avg Volume | $2.36M |
| Volume | $2.98M |
Performance Analysis
NEUTRALEDIT presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report